专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015042275A4 METHODS AND COMPOSITIONS FOR IMAGING DISORDERS USING POLYSPECIFIC AGENTS 审中-公开
标题翻译：使用多种特异性试剂成像病症的方法和组合物
公开(公告)号：WO2015042275A4
公开(公告)日：2015-06-18
申请号：PCT/US2014056332
申请日：2014-09-18
申请人： SLOAN KETTERING INST CANCER
发明人： VILLEGAS NERISSA THERESE V , LEWIS JASON S
IPC分类号： A61B5/055
CPC分类号： A61K51/1075 , A61B5/055
摘要： The present invention provides compositions and methods for detecting and/or monitoring a disease state with polyspecific imaging agents. In a particular embodiment, provided methods may be used to assess efficacy of anti-receptor tyrosine kinase and/or anti-cancer treatments. In some embodiments, the present invention provides methods and compositions relating to polyspecific imaging agents that target neurological, tumor-associated and/or intratumoral markers. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-receptor tyrosine kinase antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-receptor tyrosine kinase antibodies and/or compositions.
摘要翻译：本发明提供了用多特异性显像剂检测和/或监测疾病状态的组合物和方法。在一个具体的实施方案中，所提供的方法可用于评估抗受体酪氨酸激酶和/或抗癌治疗的功效。在一些实施方案中，本发明提供了涉及靶向神经学，肿瘤相关和/或肿瘤内标志物的多特异性显像剂的方法和组合物。例如，本发明提供包含抗受体酪氨酸激酶抗体或其片段或特征部分的组合物，包括药物组合物。本发明还提供了使用抗受体酪氨酸激酶抗体和/或组合物的各种治疗和/或诊断方法。

2. 发明申请

WO2013009655A2 USES OF LABELED HSP90 INHIBITORS 审中-公开
标题翻译：标签HSP90抑制剂的使用
公开(公告)号：WO2013009655A2
公开(公告)日：2013-01-17
申请号：PCT/US2012045861
申请日：2012-07-06
申请人： SLOAN KETTERING INST CANCER , CHIOSIS GABRIELA , PILLARSETTY NAGAVARAKISHORE , LEWIS JASON S , LARSON STEVEN M , TALDONE TONY , ALPAUGH MARY L , GOMES-DAGAMA ERICA M
发明人： CHIOSIS GABRIELA , PILLARSETTY NAGAVARAKISHORE , LEWIS JASON S , LARSON STEVEN M , TALDONE TONY , ALPAUGH MARY L , GOMES-DAGAMA ERICA M
IPC分类号： A61K51/04
CPC分类号： A61K51/0459 , A61K31/52 , G01N33/5011 , G01N33/5017 , G01N33/5044 , G01N33/574 , G01N33/57407 , G01N33/57426 , G01N2500/04 , G01N2800/52
摘要： This invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor.
摘要翻译：本发明涉及使用标记的HSP90抑制剂改善用HSP90抑制剂治疗癌症患者的各种方法，包括用于确定肿瘤是否可能对HSP90抑制剂治疗有反应的离体和体内方法。

3. 发明专利

ES2766623T3 Usos de inhibidores etiquetados HSP90 未知
公开(公告)号：ES2766623T3
公开(公告)日：2020-06-12
申请号：ES17156149
申请日：2012-07-06
申请人： SLOAN KETTERING INST CANCER RES , UNIV CORNELL
发明人： CHIOSIS GABRIELA , PILLARSETTY NAGAVARAKISHORE , LEWIS JASON S , LARSON STEVEN M , TALDONE TONY , ALPAUGH MARY L
IPC分类号： G01N33/574 , A61K31/52 , A61K51/04 , G01N33/50
摘要： Un inhibidor de HSP90 detectablemente etiquetado para su uso en un método para determinar si un tumor probablemente responderá a la terapia con un inhibidor de HSP90 que comprende o bien las etapas siguientes: (a) poner en contacto el tumor con un inhibidor de HSP90 detectablemente etiquetado que se enlaza preferencialmente a una forma específica del tumor de HSP90 presente en un tumor o células tumorales; (b) medir la cantidad de inhibidor de HSP90 etiquetado enlazado al tumor; y (c) comparar la cantidad de inhibidor de HSP90 etiquetado enlazado al tumor medida en la etapa (b) con la cantidad de referencia del inhibidor de HSP90 etiquetado enlazado a células normales; en donde una cantidad mayor de inhibidor de HSP90 etiquetado enlazado al tumor medida en la etapa (b) como se compara con la cantidad de referencia indica que el tumor probablemente responderá a la terapia con un inhibidor de HSP90; o bien que comprende las etapas siguientes: (a) administrar un inhibidor de HSP90 detectablemente etiquetado, en donde el inhibidor de HSP90 detectablemente etiquetado es una forma radioetiquetada del inhibidor de HSP90 que se enlaza preferencialmente a una forma específica del tumor de HSP90 presente en un tumor o células tumorales, al paciente en múltiples puntos de tiempo dentro del periodo durante el cual el paciente está recibiendo terapia con un inhibidor de HSP90; y (b) medir la concentración del inhibidor de HSP90 radioetiquetado en el tumor del paciente en dichos múltiples puntos de tiempo después de la administración en la etapa (a); y (c) comparar las concentraciones del inhibidor de HSP90 radioetiquetado medidas en la etapa (b) con las concentraciones mínimas del inhibidor de HSP90 necesarias para tratar efectivamente el tumor, en donde concentraciones medidas mayores que la mínima necesaria para tratar el tumor indican que el paciente es probable que responda a la terapia con el inhibidor de HSP90, en donde en ambas secuencias de etapas mencionadas anteriormente el inhibidor detectablemente etiquetado es: o una sal farmacéuticamente aceptable del mismo, en donde: X3 es CH2, CF2, S, SO, SO2, O, NH o NR2, en donde R2 es alquilo; X2 es 123I, 124I, 125I o 131I; X4 es hidrógeno o halógeno; X5 es O o CH2; R es 3-isopropilaminopropilo, 3-(isopropil(metil)amino)propilo, 3-(isopropil(etil)amino)propilo, 3-((2- hidroxietil)(isopropil)amino)propilo, 3-(metil(prop-2-inil)amino)propilo, 3-(alil(metil)amino)propilo, 3- (etil(metil)amino)propilo, 3-(ciclopropil(propil)amino)propilo, 3-(ciclohexil(2-hidroxietil)amino)propilo, 3-(2-metilaziridin- 1-il)propilo, 3-(piperidin-1-il)propilo, 3-(4-(2-hidroxietil)piperazin-1-il)propilo, 3-morfolinopropilo, 3- (trimetilamonio)propilo, 2-(isopropilamino)etilo, 2-(isobutilamino)etilo, 2-(neopentilamino)etilo, 2- (ciclopropilmetilamino)etilo, 2-(etil(metil)amino)etilo, 2-(isobutil(metil)amino)etilo o 2-(metil(prop-2-inil)amino)etilo; y n es 1 o 2.

4. 发明专利

CA2841173A1 USES OF LABELED HSP90 INHIBITORS 未知
公开(公告)号：CA2841173A1
公开(公告)日：2013-06-17
申请号：CA2841173
申请日：2012-07-06
申请人： SLOAN KETTERING INST CANCER
发明人： CHIOSIS GABRIELA , PILLARSETTY NAGAVARAKISHORE , LEWIS JASON S , LARSON STEVEN M , TALDONE TONY , ALPAUGH MARY L , GOMES-DAGAMA ERICA M
IPC分类号： A61K51/04 , A61K31/52 , A61P35/00 , G01N33/574
摘要： The invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor. The disclosure provides a method for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor which comprises the following steps: (a) contacting the tumor or a sample containing cells from the tumor with a detectably labeled HSP90 inhibitor which binds preferentially to a tumor-specific form of HSP90; (b) measuring the amount of labeled HSP90 inhibitor bound to the tumor or the tumor cells in the sample; and (c) comparing the amount of labeled HSP90 inhibitor bound to the tumor or the tumor cells in the sample measured in step (b) to the amount of labeled-HSP90 inhibitor bound to a reference.

5. 发明专利

AU2017204369B2 Uses of labeled HSP90 inhibitors 未知
公开(公告)号：AU2017204369B2
公开(公告)日：2019-08-01
申请号：AU2017204369
申请日：2017-06-27
申请人： SLOAN KETTERING INST CANCER RES
发明人： CHIOSIS GABRIELA , PILLARSETTY NAGAVARAKISHORE , LEWIS JASON S , LARSON STEVEN M , TALDONE TONY , ALPAUGH MARY L , GOMES-DAGAMA ERICA M
IPC分类号： A61K51/04 , G01N33/50
摘要： USES OF LABELED HSP90 INIHIBITORS Abstract of the Disclosure This invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor.

6. 发明专利

CA2841173C USES OF LABELED HSP90 INHIBITORS 未知
公开(公告)号：CA2841173C
公开(公告)日：2022-06-21
申请号：CA2841173
申请日：2012-07-06
申请人： SLOAN KETTERING INST CANCER RES
发明人： CHIOSIS GABRIELA , PILLARSETTY NAGAVARAKISHORE , LEWIS JASON S , LARSON STEVEN M , TALDONE TONY , ALPAUGH MARY L , GOMES-DAGAMA ERICA M
IPC分类号： G01N33/574
摘要： The invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor. The disclosure provides a method for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor which comprises the following steps: (a) contacting the tumor or a sample containing cells from the tumor with a detectably labeled HSP90 inhibitor which binds preferentially to a tumor-specific form of HSP90; (b) measuring the amount of labeled HSP90 inhibitor bound to the tumor or the tumor cells in the sample; and (c) comparing the amount of labeled HSP90 inhibitor bound to the tumor or the tumor cells in the sample measured in step (b) to the amount of labeled-HSP90 inhibitor bound to a reference.

7. 发明专利

MX2014000292A USOS DE INHIBIDORES ETIQUETADOS HSP90. 未知
公开(公告)号：MX2014000292A
公开(公告)日：2015-03-06
申请号：MX2014000292
申请日：2012-07-06
申请人： SLOAN KETTERING INST CANCER
发明人： CHIOSIS GABRIELA , ALPAUGH MARY L , NAGAVARAKISHORE PILLARSETTY , LEWIS JASON S , LARSON STEVEN M , TONY TALDONE , ERICA M GOMES-DAGAMA
IPC分类号： G01N33/50
摘要： Esta invención se refiere a diversos métodos de uso de inhibidores etiquetados HSP90 para mejorar el tratamiento de pacientes con cáncer con inhibidores HSP90, incluyendo métodos ex vivo e in vivo para determinar si un tumor responderá probablemente a la terapia con un inhibidor HSP90.

8. 发明专利

SG11201610004PA MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF 未知
公开(公告)号：SG11201610004PA
公开(公告)日：2016-12-29
申请号：SG11201610004P
申请日：2015-06-01
申请人： SLOAN KETTERING INST CANCER
发明人： GIN DAVID Y , CHEA ERIC K , FERNANDEZ-TEJADA ALBERTO , TAN DEREK S , LEWIS JASON S , GARDNER JEFFREY R , PILLARSETTY NAGAVARAKISHORE
IPC分类号： A61K31/7024 , C07H13/08 , C07H15/24
摘要： Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.

9. 发明专利

AU2012282903A1 Uses of labeled HSP90 inhibitors 未知
公开(公告)号：AU2012282903A1
公开(公告)日：2014-02-13
申请号：AU2012282903
申请日：2012-07-06
申请人： SLOAN KETTERING INST CANCER RES
发明人： CHIOSIS GABRIELA , PILLARSETTY NAGAVARAKISHORE , LEWIS JASON S , LARSON STEVEN M , TALDONE TONY , ALPAUGH MARY L , GOMES-DAGAMA ERICA M
IPC分类号： A61K51/04 , G01N33/50
摘要： The invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor. The disclosure provides a method for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor which comprises the following steps: (a) contacting the tumor or a sample containing cells from the tumor with a detectably labeled HSP90 inhibitor which binds preferentially to a tumor-specific form of HSP90; (b) measuring the amount of labeled HSP90 inhibitor bound to the tumor or the tumor cells in the sample; and (c) comparing the amount of labeled HSP90 inhibitor bound to the tumor or the tumor cells in the sample measured in step (b) to the amount of labeled-HSP90 inhibitor bound to a reference.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式